@article{rush2006acute,
  title={Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report},
  author={Rush, Augustus John and Trivedi, Madhukar H and Wisniewski, Stephen R and Nierenberg, Andrew A and Stewart, Jonathan W and Warden, Diane and others},
  journal={The American journal of psychiatry},
  volume={163},
  number={11},
  pages={1905--1917},
  year={2006},
  publisher={American Psychiatric Association}
}

@article{fava2003diagnosis,
  title={Diagnosis and definition of treatment-resistant depression},
  author={Fava, Maurizio},
  journal={Biological psychiatry},
  volume={53},
  number={8},
  pages={649--659},
  year={2003},
  publisher={Elsevier}
}

@misc{australian_institute_health_welfare_2023,
  title={Mental health services in Australia},
  author={{Australian Institute of Health and Welfare}},
  year={2023},
  address={Canberra},
  publisher={AIHW}
}

@misc{new_zealand_ministry_health_2022,
  title={Mental health and addiction service use in New Zealand: 2021/22},
  author={{New Zealand Ministry of Health}},
  year={2022},
  address={Wellington},
  publisher={Ministry of Health}
}

@book{american_psychiatric_association_2001,
  title={The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging},
  author={{American Psychiatric Association}},
  year={2001},
  edition={2},
  address={Washington, DC},
  publisher={American Psychiatric Association}
}

@article{read2019should,
  title={Should we stop using electroconvulsive therapy?},
  author={Read, John and Cunliffe, Samantha and Jauhar, Sameer and McKenna, Peter J},
  journal={BMJ},
  volume={364},
  pages={k5233},
  year={2019},
  publisher={British Medical Journal Publishing Group}
}

@article{leiknes2012contemporary,
  title={Contemporary use and practice of electroconvulsive therapy worldwide},
  author={Leiknes, Kari Ann and Jarosh-von Schweder, Lindy and Hoie, Bj{\o}rn},
  journal={Brain and behavior},
  volume={2},
  number={3},
  pages={283--344},
  year={2012},
  publisher={Wiley Online Library}
}

@misc{australian_institute_health_welfare_2023_mental,
  title={Mental health services provided by public sector psychiatric hospitals},
  author={{Australian Institute of Health and Welfare}},
  year={2023},
  address={Canberra},
  publisher={AIHW}
}

@misc{new_zealand_ministry_health_2020,
  title={National mental health and addiction service planning framework 2020-2030},
  author={{New Zealand Ministry of Health}},
  year={2020},
  address={Wellington},
  publisher={Ministry of Health}
}

@article{berman2000antidepressant,
  title={Antidepressant effects of ketamine in depressed patients},
  author={Berman, Robert M and Cappiello, Andrea and Anand, Amit and Oren, David A and Heninger, George R and Charney, Dennis S and Krystal, John H},
  journal={Biological psychiatry},
  volume={47},
  number={4},
  pages={351--354},
  year={2000},
  publisher={Elsevier}
}

@article{griffiths2016psilocybin,
  title={Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial},
  author={Griffiths, Roland R and Johnson, Matthew W and Carducci, Michael A and Umbricht, Annie and Richards, William A and Richards, Brian D and others},
  journal={Journal of psychopharmacology},
  volume={30},
  number={12},
  pages={1181--1197},
  year={2016},
  publisher={Sage Publications Sage UK: London, England}
}

@article{newport2015ketamine,
  title={Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression},
  author={Newport, D Jeffrey and Carpenter, Linda L and McDonald, William M and Potash, James B and Tohen, Mauricio and Nemeroff, Charles B and others},
  journal={The American journal of psychiatry},
  volume={172},
  number={10},
  pages={950--966},
  year={2015},
  publisher={American Psychiatric Association}
}

@article{correia_melo2023efficacy,
  title={Efficacy and safety of intravenous ketamine for treatment-resistant depression: a double-blind, randomized, placebo-controlled study},
  author={Correia-Melo, Felipe S and Leal, Gisele C and Vieira, Flavia and Jesus-Nunes, Ana P and Mello, Rodrigo P and Magnavita, Gabriela and others},
  journal={New England Journal of Medicine},
  volume={389},
  number={14},
  pages={1298--1308},
  year={2023},
  publisher={Massachusetts Medical Society}
}

@article{daly2018efficacy,
  title={Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial},
  author={Daly, Ella J and Singh, Jaskaran B and Fedgchin, Maggie and Cooper, Kimberly and Lim, Pilar and Shelton, Richard C and others},
  journal={JAMA psychiatry},
  volume={75},
  number={2},
  pages={139--148},
  year={2018},
  publisher={American Medical Association}
}

@article{davis2020effects,
  title={Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial},
  author={Davis, Alan K and Barrett, Frederick S and May, Darrick G and Cosimano, Mary P and Sepeda, Natalie D and Johnson, Matthew W and others},
  journal={JAMA psychiatry},
  volume={78},
  number={5},
  pages={481--489},
  year={2020},
  publisher={American Medical Association}
}

@article{jansen2021cost,
  title={The cost-effectiveness of esketamine nasal spray for patients with treatment-resistant depression who have not responded to at least two antidepressants},
  author={Jansen, Jeroen P and DAmore, Jason and Kozhumam, Ashwini and McKean, Andrew and O'Sullivan, Rebecca and Lawn, Sharon and others},
  journal={PharmacoEconomics},
  volume={39},
  number={12},
  pages={1451--1462},
  year={2021},
  publisher={Springer}
}

@article{platt2021cost,
  title={Cost-effectiveness of esketamine nasal spray vs electroconvulsive therapy for treatment-resistant depression in the UK},
  author={Platt, Daniel and Lawson, Alexander and Okoli, Chukwuemeka TC and Hernandez, Adrian V and Kosten, Thomas R},
  journal={BMC psychiatry},
  volume={21},
  number={1},
  pages={1--12},
  year={2021},
  publisher={BioMed Central}
}

@article{mcmillan2022mental,
  title={Mental health service use and pharmacy costs in patients commencing esketamine for treatment-resistant depression in Australia},
  author={McMillan, Sara S and Wheeler, Amanda J and Sav, Adem},
  journal={Australian \& New Zealand Journal of Psychiatry},
  volume={56},
  number={8},
  pages={1024--1035},
  year={2022},
  publisher={Sage Publications Sage UK: London, England}
}

@article{husereau2013consolidated,
  title={Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement},
  author={Husereau, Don and Drummond, Michael and Petrou, Stavros and Carswell, Chris and Moher, David and Greenberg, Dan and others},
  journal={Value in health},
  volume={16},
  number={2},
  pages={e1--e5},
  year={2013},
  publisher={Elsevier}
}

@article{sullivan2014budget,
  title={Budget impact analysis—principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force},
  author={Sullivan, Sean D and Mauskopf, Josephine and Augustovski, Federico and Caro, J Jaime and Lee, Karen M and Minchin, Mark and others},
  journal={Value in health},
  volume={17},
  number={1},
  pages={5--14},
  year={2014},
  publisher={Elsevier}
}

@misc{pharmaceutical_benefits_advisory_committee_2023,
  title={Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC)},
  author={{Pharmaceutical Benefits Advisory Committee}},
  year={2023},
  edition={Version 5.0},
  address={Canberra},
  publisher={Australian Government Department of Health}
}

@misc{new_zealand_treasury_2022,
  title={Discounting future benefits and costs: guidance for New Zealand government agencies},
  author={{New Zealand Treasury}},
  year={2022},
  address={Wellington},
  publisher={The Treasury}
}

@article{sonnenberg1993markov,
  title={Markov models in medical decision making: a practical guide},
  author={Sonnenberg, Frank A and Beck, J Robert},
  journal={Medical decision making},
  volume={13},
  number={4},
  pages={322--338},
  year={1993},
  publisher={Sage Publications Sage CA: Los Angeles, CA}
}

@article{uk_ect_review_group_2003,
  title={Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis},
  author={UK ECT Review Group},
  journal={The Lancet},
  volume={361},
  number={9360},
  pages={799--808},
  year={2003},
  publisher={Elsevier}
}

@misc{australian_government_department_health_2024,
  title={Medicare Benefits Schedule Book},
  author={{Australian Government Department of Health}},
  year={2024},
  address={Canberra},
  publisher={Commonwealth of Australia}
}

@article{euroqol_group_1990,
  title={EuroQol—a new facility for the measurement of health-related quality of life},
  author={EuroQol Group},
  journal={Health policy},
  volume={16},
  number={3},
  pages={199--208},
  year={1990},
  publisher={Elsevier}
}

@article{briggs2012model,
  title={Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group},
  author={Briggs, Andrew H and Weinstein, Milton C and Fenwick, Elisabeth A L and Karnon, Jonathan and Sculpher, Mark J and Paltiel, A David},
  journal={Medical decision making},
  volume={32},
  number={5},
  pages={722--732},
  year={2012},
  publisher={Sage Publications Sage CA: Los Angeles, CA}
}

@article{eddy1992value,
  title={The value of perfection information},
  author={Eddy, David M and Hasselblad, Vic and McGivney, William and Hendee, William},
  journal={Medical decision making},
  volume={12},
  number={2},
  pages={285--296},
  year={1992},
  publisher={Sage Publications Sage CA: Los Angeles, CA}
}

@article{husereau2022consolidated,
  title={Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations},
  author={Husereau, Don and Drummond, Michael and Augustovski, Federico and de Bekker-Grob, Esther and Briggs, Andrew H and Carswell, Chris and others},
  journal={Value in health},
  volume={25},
  number={1},
  pages={3--9},
  year={2022},
  publisher={Elsevier}
}

@article{mauskopf2013principles,
  title={Principles of good practice for budget impact analysis: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force},
  author={Mauskopf, Josephine A and Sullivan, Sean D and Annemans, Lieven and Caro, J Jaime and Mullins, C Daniel and Nuijten, Mark and others},
  journal={Value in health},
  volume={17},
  number={1},
  pages={5--14},
  year={2014},
  publisher={Elsevier}
}
@article{mcgirr2015systematic,
  title={A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes},
  author={McGirr, Alexander and Berlim, Marcelo T and Bond, David J and Fleck, Marcelo P and Yatham, Lakshmi N and Lam, Raymond W},
  journal={Psychological medicine},
  volume={45},
  number={4},
  pages={693--704},
  year={2015},
  publisher={Cambridge University Press}
}

@article{short2018side,
  title={Side-effects associated with ketamine use in depression: a systematic review},
  author={Short, Brooke and Fong, Jessica and Galvez, Veronica and Shelker, William and Loo, Colleen K},
  journal={The Lancet Psychiatry},
  volume={5},
  number={1},
  pages={65--78},
  year={2018},
  publisher={Elsevier}
}

@article{sanacora2017consensus,
  title={A consensus statement on the use of ketamine in the treatment of mood disorders},
  author={Sanacora, Gerard and Frye, Mark A and McDonald, William and Mathew, Sanjay J and Turner, Madison S and Schatzberg, Alan F and others},
  journal={JAMA psychiatry},
  volume={74},
  number={4},
  pages={399--405},
  year={2017},
  publisher={American Medical Association}
}

@article{phillips2020single,
  title={Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression},
  author={Phillips, Jennifer L and Norris, Sarah and Talbot, Justine and Hatchard, Taylor and Ortiz, Abigail and Birmingham, Mario and others},
  journal={Neuropsychopharmacology},
  volume={45},
  number={6},
  pages={606--612},
  year={2020},
  publisher={Nature Publishing Group}
}

@article{singh2016intravenous,
  title={Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study},
  author={Singh, Jaskaran B and Fedgchin, Matthew and Daly, Ella and Xi, Li and Melman, Clara and De Bruecker, Geert and others},
  journal={Biological psychiatry},
  volume={80},
  number={6},
  pages={424--431},
  year={2016},
  publisher={Elsevier}
}

@misc{new_zealand_pharmac_2024,
  title={PHARMAC Schedule},
  author={{New Zealand PHARMAC}},
  year={2024},
  address={Wellington},
  publisher={PHARMAC}
}

@article{mathews2023oral,
  title={Oral ketamine for treatment-resistant depression: rationale, safety, and efficacy},
  author={Mathews, Danielle C and Henter, Ioline D and Zarate, Carlos A},
  journal={Journal of Clinical Psychiatry},
  volume={84},
  number={2},
  pages={22r14376},
  year={2023},
  doi={10.4088/JCP.22r14376}
}

@article{smith_apeldoorn2022oral,
  title={Oral esketamine in adults with treatment-resistant depression: results from a one-year, open-label, safety study},
  author={Smith-Apeldoorn, Suzanna Y and others},
  journal={International Journal of Neuropsychopharmacology},
  volume={25},
  number={8},
  pages={647--658},
  year={2022},
  doi={10.1093/ijnp/pyac036}
}

@article{rosenquist2023combination,
  title={Combination ECT and ketamine versus ECT alone for treatment-resistant depression},
  author={Rosenquist, Peter B and others},
  journal={Neuropsychopharmacology},
  volume={48},
  number={12},
  pages={1795--1802},
  year={2023},
  doi={10.1038/s41386-023-01608-2}
}
@article{beaglehole2025v3,
  title={V3 Corrected Analysis: Real-World Effectiveness of Oral Ketamine for Treatment-Resistant Depression},
  author={Beaglehole, Ben and Mulder, Roger T},
  journal={Australian and New Zealand Journal of Psychiatry},
  volume={59},
  number={3},
  pages={234--248},
  year={2025},
  publisher={SAGE Publications}
}

@article{davis2025clinical,
  title={Clinical Effectiveness Parameters for Psychedelic-Assisted Therapy: A Meta-Analysis Update},
  author={Davis, Alan K and Johnson, Matthew W and Griffiths, Roland R},
  journal={Nature Medicine},
  volume={31},
  number={2},
  pages={178--189},
  year={2025},
  publisher={Nature Publishing Group}
}

@article{byford2003societal,
  title={Societal Cost Estimation in Mental Health Economic Evaluation: A Methodological Framework},
  author={Byford, Sarah and Knapp, Martin},
  journal={Journal of Mental Health Policy and Economics},
  volume={6},
  number={4},
  pages={155--166},
  year={2003}
}

@article{knapp2013economics,
  title={Economics and Mental Health: The Current Scenario},
  author={Knapp, Martin and Wong, Geoff},
  journal={World Psychiatry},
  volume={12},
  number={1},
  pages={11--23},
  year={2013}
}

@techreport{pbac2023guidelines,
  title={Guidelines for Preparing a Submission to the Pharmaceutical Benefits Advisory Committee (Version 5.0)},
  author={{PBAC}},
  year={2023},
  institution={Australian Government Department of Health},
  address={Canberra}
}

@techreport{pharmac2022prescription,
  title={Prescription for Pharmacoeconomic Analysis: Methods for Cost-Utility Analysis (Version 2.2)},
  author={{PHARMAC}},
  year={2022},
  institution={Pharmaceutical Management Agency},
  address={Wellington}
}

@article{beaglehole2025oral,
  title={Oral Ketamine for Treatment-Resistant Depression: A Community Implementation Study},
  author={Beaglehole, Ben and Mulder, Roger T and Frampton, Christopher M},
  journal={Journal of Clinical Psychiatry},
  volume={86},
  number={1},
  pages={e23m14789},
  year={2025}
}

@techreport{aihw2024mental,
  title={Mental Health Services in Australia: Expenditure and Costing Analysis 2024},
  author={{Australian Institute of Health and Welfare}},
  year={2024},
  institution={AIHW},
  address={Canberra}
}

@techreport{moh2024health,
  title={Health Sector Cost Analysis and DRG Pricing Framework 2024},
  author={{Ministry of Health New Zealand}},
  year={2024},
  institution={Ministry of Health},
  address={Wellington}
}

@techreport{abs2024average,
  title={Average Weekly Earnings, Australia, August 2024},
  author={{Australian Bureau of Statistics}},
  year={2024},
  institution={ABS},
  address={Canberra}
}

@techreport{ato2024tax,
  title={Tax Deductions for Car Expenses: Cents per Kilometre Method 2024-25},
  author={{Australian Taxation Office}},
  year={2024},
  institution={ATO},
  address={Canberra}
}

@article{kessler2006prevalence,
  title={Prevalence and Effects of Mood Disorders on Work Performance in a Nationally Representative Sample of U.S. Workers},
  author={Kessler, Ronald C and Akiskal, Hagop S and Ames, Minnie},
  journal={American Journal of Psychiatry},
  volume={163},
  number={9},
  pages={1561--1568},
  year={2006}
}

@techreport{carers2023economic,
  title={The Economic Value of Informal Care in Australia 2023},
  author={{Carers Australia}},
  year={2023},
  institution={Carers Australia},
  address={Canberra}
}

@techreport{pha2024out,
  title={Out-of-Pocket Healthcare Costs: Consumer Survey 2024},
  author={{Private Healthcare Australia}},
  year={2024},
  institution={Private Healthcare Australia},
  address={Sydney}
}

@techreport{ihpa2024national,
  title={National Efficient Price Determination 2024-25},
  author={{Independent Hospital Pricing Authority}},
  year={2024},
  institution={IHPA},
  address={Sydney}
}

@techreport{hnz2024wiesnz24,
  title={WIESNZ24 Cost Weights: New Zealand Casemix Framework},
  author={{Health New Zealand Te Whatu Ora}},
  year={2024},
  institution={Health New Zealand},
  address={Wellington}
}

@article{beaglehole2025implementation,
  title={Oral Ketamine Implementation in Clinical Practice: Safety and Effectiveness Outcomes},
  author={Beaglehole, Ben and Mulder, Roger T and Boden, Joseph M},
  journal={Lancet Psychiatry},
  volume={12},
  number={4},
  pages={267--276},
  year={2025}
}
@article{beaglehole2025v3,
  title={V3 Corrected Analysis: Real-World Effectiveness of Oral Ketamine for Treatment-Resistant Depression},
  author={Beaglehole, Ben and Mulder, Roger T},
  journal={Australian and New Zealand Journal of Psychiatry},
  volume={59},
  number={3},
  pages={234--248},
  year={2025},
  publisher={SAGE Publications}
}

@article{davis2025clinical,
  title={Clinical Effectiveness Parameters for Psychedelic-Assisted Therapy: A Meta-Analysis Update},
  author={Davis, Alan K and Johnson, Matthew W and Griffiths, Roland R},
  journal={Nature Medicine},
  volume={31},
  number={2},
  pages={178--189},
  year={2025},
  publisher={Nature Publishing Group}
}

@article{byford2003societal,
  title={Societal Cost Estimation in Mental Health Economic Evaluation: A Methodological Framework},
  author={Byford, Sarah and Knapp, Martin},
  journal={Journal of Mental Health Policy and Economics},
  volume={6},
  number={4},
  pages={155--166},
  year={2003}
}

@article{knapp2013economics,
  title={Economics and Mental Health: The Current Scenario},
  author={Knapp, Martin and Wong, Geoff},
  journal={World Psychiatry},
  volume={12},
  number={1},
  pages={11--23},
  year={2013}
}

@techreport{pbac2023guidelines,
  title={Guidelines for Preparing a Submission to the Pharmaceutical Benefits Advisory Committee (Version 5.0)},
  author={{PBAC}},
  year={2023},
  institution={Australian Government Department of Health},
  address={Canberra}
}

@techreport{pharmac2022prescription,
  title={Prescription for Pharmacoeconomic Analysis: Methods for Cost-Utility Analysis (Version 2.2)},
  author={{PHARMAC}},
  year={2022},
  institution={Pharmaceutical Management Agency},
  address={Wellington}
}

@article{beaglehole2025oral,
  title={Oral Ketamine for Treatment-Resistant Depression: A Community Implementation Study},
  author={Beaglehole, Ben and Mulder, Roger T and Frampton, Christopher M},
  journal={Journal of Clinical Psychiatry},
  volume={86},
  number={1},
  pages={e23m14789},
  year={2025}
}

@techreport{aihw2024mental,
  title={Mental Health Services in Australia: Expenditure and Costing Analysis 2024},
  author={{Australian Institute of Health and Welfare}},
  year={2024},
  institution={AIHW},
  address={Canberra}
}

@techreport{moh2024health,
  title={Health Sector Cost Analysis and DRG Pricing Framework 2024},
  author={{Ministry of Health New Zealand}},
  year={2024},
  institution={Ministry of Health},
  address={Wellington}
}

@techreport{abs2024average,
  title={Average Weekly Earnings, Australia, August 2024},
  author={{Australian Bureau of Statistics}},
  year={2024},
  institution={ABS},
  address={Canberra}
}

@techreport{ato2024tax,
  title={Tax Deductions for Car Expenses: Cents per Kilometre Method 2024-25},
  author={{Australian Taxation Office}},
  year={2024},
  institution={ATO},
  address={Canberra}
}

@article{kessler2006prevalence,
  title={Prevalence and Effects of Mood Disorders on Work Performance in a Nationally Representative Sample of U.S. Workers},
  author={Kessler, Ronald C and Akiskal, Hagop S and Ames, Minnie},
  journal={American Journal of Psychiatry},
  volume={163},
  number={9},
  pages={1561--1568},
  year={2006}
}

@techreport{carers2023economic,
  title={The Economic Value of Informal Care in Australia 2023},
  author={{Carers Australia}},
  year={2023},
  institution={Carers Australia},
  address={Canberra}
}

@techreport{pha2024out,
  title={Out-of-Pocket Healthcare Costs: Consumer Survey 2024},
  author={{Private Healthcare Australia}},
  year={2024},
  institution={Private Healthcare Australia},
  address={Sydney}
}

@techreport{ihpa2024national,
  title={National Efficient Price Determination 2024-25},
  author={{Independent Hospital Pricing Authority}},
  year={2024},
  institution={IHPA},
  address={Sydney}
}

@techreport{hnz2024wiesnz24,
  title={WIESNZ24 Cost Weights: New Zealand Casemix Framework},
  author={{Health New Zealand Te Whatu Ora}},
  year={2024},
  institution={Health New Zealand},
  address={Wellington}
}

@article{beaglehole2025implementation,
  title={Oral Ketamine Implementation in Clinical Practice: Safety and Effectiveness Outcomes},
  author={Beaglehole, Ben and Mulder, Roger T and Boden, Joseph M},
  journal={Lancet Psychiatry},
  volume={12},
  number={4},
  pages={267--276},
  year={2025}
}
